Trial Profile

Efficacy, Safety, and Immunogenicity of RotaTeq Among Infants in Asia and Africa.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rotavirus W179-9 vaccine (Primary)
Indications Gastroenteritis; Rotavirus infections
Focus Pharmacodynamics; Registrational; Therapeutic Use
Acronyms COMPLETED
Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

17 Oct 2016 Results of a post-hoc analysis were published in the Pediatric Infectious Disease Journal
06 Aug 2010 Results in children from Africa published in Lancet.
06 Aug 2010 Results in children from Asia published in Lancet.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com